Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P55789
UPID:
ALR_HUMAN
Alternative names:
Augmenter of liver regeneration; Hepatopoietin
Alternative UPACC:
P55789; Q53YM6; Q8TAH6; Q9H290; Q9UK40
Background:
FAD-linked sulfhydryl oxidase ALR, also known as Augmenter of liver regeneration and Hepatopoietin, plays a crucial role in mitochondrial function. It acts as a FAD-dependent sulfhydryl oxidase, essential for regenerating redox-active disulfide bonds in CHCHD4/MIA40. This process is vital for protein folding in the mitochondrial intermembrane space, highlighting ALR's significance in cellular health and energy production.
Therapeutic significance:
ALR's involvement in mitochondrial progressive myopathy, congenital cataract, hearing loss, and developmental delay underscores its therapeutic potential. Understanding the role of FAD-linked sulfhydryl oxidase ALR could open doors to potential therapeutic strategies for these conditions, offering hope for targeted treatments.